Official Journal of Research Center for Gastroenterology and Liver Diseases
Outline
Statin, Beyond Hyperlipidemia toward a Novel Agent for Hepatitis C & Authors' Reply
Authors
Abstract
Dear Editor,
We read with great interest the article by Malaguarnera et al. (1) in this issue of Hepatitis monthly, in which the safety and efficacy of rosuvastatin plus interferon and ribavirin were evaluated in a randomized controlled trial. Sustained viral response was observed in 40% of the standard-care group and 51% of the triple-therapy group, and this was associated with improvement of steatosis and fibrosis without causing side effects. Despite the importance of this study, we think that the clinical implications extracted from this study deserve further evaluation. In particular, we question some components of the study design.
References
- 1.The references are available in the PDF file.
Copyright
© 2011, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
Rosuvastatin and chronic hepatitis C
Yoshida E. Rosuvastatin and chronic hepatitis C. Hepat Mon. 2011;11(5):. doi:
Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with ?-interferon and ribavirin
Vacante M, Russo C, Gargante M, Giordano M, Bertino G, et al. Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with ?-interferon and ribavirin. Hepat Mon. 2011;11(2):. doi:
Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks
DAmbrosio R, Aghemo A. Treatment of Patients With HCV Related Cirrhosis: Many Rewards With Very Few Risks. Hepat Mon. 2012;12(6):. doi: https://doi.org/10.5812/hepatmon.6095
Hydroxyurea: A useful adjunct to the standard antiviral therapy in chronic hepatitis B
Dong C, Dai X, Liang J, Dong M, Meng J. Hydroxyurea: A useful adjunct to the standard antiviral therapy in chronic hepatitis B. Hepat Mon. 2012;12(6):. doi: https://doi.org/10.5812/hepatmon.6194
Hydroxyurea: A useful adjunct to the standard antiviral therapy in chronic hepatitis B
Mostaghni A, Soltanian A, Mokhtari E, Japoni S, Mehrabani D. Hydroxyurea: A useful adjunct to the standard antiviral therapy in chronic hepatitis B. Hepat Mon. 2011;11(3):. doi:
More by these authors
- Scopus by DOI: 0
Last Update: 1 month ago
- Scopus by Title: 0
Last Update: 1 month ago
- Scopus by Title (Ref): 0
Last Update: 1 month ago
- CrossRef: 0
Last Update: 1 day ago